Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Kreimendahl

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Evaluating Working Ability and Quality of Life of Patients with Multiple SclerosisF Kreimendahl, R P T Rychlik, S Patel, et al.
Biomedizinische Technik. Biomedical Engineering|February 13, 2019
Session 8: Biomaterials - HydrogelsH Stratesteffen, M Köpf, F Kreimendahl, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Working Ability and Monetarily Valued Productivity of Patients with Multiple Sclerosis Treated with NatalizumabF Kreimendahl, R P T Rychlik, S Patel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 18, 2023
Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST studyS Gerdes, M Hoffmann, K Asadullah, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Evaluating Working Ability and Quality of Life of Patients with Multiple SclerosisF Kreimendahl, R P T Rychlik, S Patel, et al.
Biomedizinische Technik. Biomedical Engineering|February 13, 2019
Session 8: Biomaterials - HydrogelsH Stratesteffen, M Köpf, F Kreimendahl, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Working Ability and Monetarily Valued Productivity of Patients with Multiple Sclerosis Treated with NatalizumabF Kreimendahl, R P T Rychlik, S Patel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|July 18, 2023
Effectiveness, safety and quality-of-life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non-interventional, prospective, German multicentre PERSIST studyS Gerdes, M Hoffmann, K Asadullah, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 1, 2023
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the ongoing phase IIIb randomized, double-blind, parallel-group, GUIDE studyK Schäkel, K Reich, K Asadullah, et al.
Pageof 1